From our 2025 #BioCentury financial markets preview: www.biocentury.com/article/654637

Roche reboot. Plus five updates on Trump 2.0 Once pharma’s oncology powerhouse, Roche (SIX:ROG; OTCQB:RHHBY) is charting a new course that extends beyond its traditional stronghold in cancer therapeut...

Latest #BioCentury podcast - Remaking #Roche and 5 updates about #Trump 2.0: www.biocentury.com/article/6551...

When private #biotech raised money in 2020-22, it was often at inflated valuations that no longer match public investor expectations. So where are we in the process of the Great Biotech Valuation Reset? Our #BioCentury analysis suggests about halfway. Story here: www.biocentury.com/article/654812

"Biotech companies are not sold, they are bought." #Centerview Eric Tokat comment on how pharmas drive biotech M&A. At #BioCentury and #BIA Investor and CEO Showcase in London

Pharmas challenging Novo and Lilly in obesity Eli Lilly and Novo Nordisk have clearly set themselves apart from other pharmas in the scale of their pipelines, revenues and business development activiti...

$LLY and $NVO are the clear leaders in #obesity, but which other pharmas are making a push to compete in what will be the largest therapeutic indication for #biopharma? My story in #biocentury on who's in and who's out: www.biocentury.com/article/654168